BDX · Becton Dickinson & Co
$176.80
-1.27 (-0.71%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$49.57B
Shares
272.39M
Volume · Oct 2
1.87M
Avg daily vol (3M)
1.79M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$176.80
Open$177.46
Day$175.71–178.13
52W close$138.67–192.00
Avg vol 30d1.8M
Short int11.3M · 4.2% float · 7.2d
Short vol50%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$22.41B
Trailing 12 months
Net income (TTM)
$941.00M
Trailing 12 months
Revenue growth YoY
+5.4%
Year over year
Operating margin
10.3%
Trailing 12 months
P / E (TTM)
89.0
Trailing earnings · reciprocal yield 1.1%
FCF yield
6.5%
TTM · current market cap
Return on invested capital
5.0%
Trailing 12 months
Net cash
−$16.10B
Latest balance sheet
Dividend yield
2.1%
Trailing 12 months
Shares change YoY
-4.2%
Year over year · fewer shares
Price change (1Y)
—
Trailing year
Short interest
4.2%
Latest settlement · 7.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
−2%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
71%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+14%
trailing
YTD return
+16%
this year
Relative strength
+2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $180 › 200d $163 — 50d above 200d
Institutional flow
Distributing
9 of 1,454 funds reported for Sep 30 · net -8.2K sh shares · +1 new
Insider flow
Distributing
Net -$440.9K over 90 days · 100% sells
Short interest
Rising
4.15% of float · ▲ +6.0% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1,454 holders — near 3-yr low, contrarian setup
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
35%
contracting
EPS growth
−1%
Y/Y
Free cash flow
$3.9B
Buyback
$2.3B
authorized
Balance sheet
$18.6B
net debt
Quant / Vol
risk profile
Volatility
26%
annualized · 1-yr
Max drawdown
−24%
past year
ATR
2.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Adjusted Diluted EPS
· Full Year Fiscal 2026
Non-GAAP
Initiated
$12.62 – $12.72
Guided vs delivered
· last 3 settled
Total FY 2024 Revenues
Full Year FY 2024
guided $20.1B
$20.18B
Beat +0.4%
Total FY 2023 Revenues from Continuing Operations
Full Year FY2023
guided $19.3B
$19.37B
Beat +0.4%
Reported revenues
fiscal '22
guided $19.55B – $19.75B
$18.87B
Miss −4.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
71%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $180 › 200d $163 — 50d above 200d
Institutional flow
Distributing
9 of 1,454 funds reported for Sep 30 · net -8.2K sh shares · +1 new
Insider flow
Distributing
Net -$440.9K over 90 days · 100% sells
Short interest
Rising
4.15% of float · ▲ +6.0% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1,454 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $139
Now $177 · 71%
Range high $192
vs 200-day avg +9%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Diluted Earnings per Share from Continuing Operations non-GAAP | $8.59 | Nine Months Ended June 30, 2026 | — |
| Free Cash Flow non-GAAP | $1.73B | Nine Months Ended June 30, 2026 | — |
| Net Cash Provided by Continuing Operating Activities | $2.1B | Nine Months Ended June 30, 2026 | — |
| Segment income as % of BioPharma Systems revenues | 38.6% | three months ended June 30, 2026 filing | — |
| Segment income as % of Connected Care revenues | 32.3% | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDX
this stock
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -30.8% | +20.5% | 46.5 | 2.3% |
|
MDLN
Medline Inc.
|
$45.62B | -15.2% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -9.1% | +13.4% | 21.3 | 9.8% |
|
ALC
Alcon Inc
|
$31.52B | -19.1% | +10.5% | — | 3.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDX | -3.8% | -5.8% | +13.8% | -1.2% | +15.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -3.6% | -5.3% | +1.6% | -2.2% | +3.0% |
Capital returns
Latest dividend
$1.05
/ share · ex Sep 9, 2026
Paid (TTM)
$3.9755
/ share · 4 payouts
Dividend yield (TTM, derived)
2.25%
Buyback programs
· 2 active
· as of Jun 30, 2026
Authorized (total)
$2.25B
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.